A Phase I dose-escalation study of ValloVax for the treatment of non-small stage lung cancer

Trial Profile

A Phase I dose-escalation study of ValloVax for the treatment of non-small stage lung cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs Placental-derived cell therapy-(ValloVax) (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Jan 2016 According to a Batu Biologics media release, the company expects FDA clearance in the first quarter of 2016 and trial initiation in the second quarter of 2016.
    • 26 Jan 2016 Planned initiation date changed from 30 Jun 2015 to 1 Apr 2016, based on the information provided in a Batu Biologics media release.
    • 19 May 2015 According to a Batu Biologics media release, this trial is expected to begin in the third quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top